Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Accelerated Approval
View:
Comment by ScienceFirst on Jun 29, 2023 7:53pm
    ACCELERATED APPROVAL For many medications, the effects and benefits take years to understand or appear. Taking that into account, the FDA has developed procedures to expedite the approval of these medications. The same year the FDA established the PDUFA, it instituted accelerated approval regulations. In 2021, 28% of approved drugs went through the ...more  
Comment by Rumpl3StiltSkin on Jun 29, 2023 8:08pm
With the BCG shortage and lack of anything even close, sorry Keytruda, It would seem 1433 would be granted AA? 
Comment by Jaro1977 on Jun 29, 2023 8:44pm
Roger expined that we have to go through all the steps, no cutting corners, BTD and AA will move us through the line faster but no stages can be skipped
Comment by Rumpl3StiltSkin on Jun 29, 2023 9:52pm
Well that is interesting, If that was stated it sounds like what some here have been thinking lately. First we get BTD, then apply for AA. The numbers are good enough. Final FDA approval won't come until study 2 is complete. But AA could happen some time after they are granted BTD. At least that is what I've been thinking.
Comment by ScienceFirst on Jun 29, 2023 10:11pm
AA has always been after BTD.  TLT will also qualify for Priority Review, shaving another 6 months to market. AA will allow us to charge for treatment, so to cover our cost and more.
Comment by stocksnbonds458 on Jul 02, 2023 2:46pm
Science, in my opinion AA  provides us with the 30 pound sledgehammer required for negotiations with big pharma, and I don't mean a JV. I mean a buyout. Remember, JV= ,  Buyout =
Comment by DeathXray33 on Jul 03, 2023 12:20pm
Osmium 1829; colon cancer... I buy every week no matter the price... >1.072 mil
Comment by Rumpl3StiltSkin on Jul 04, 2023 2:29pm
Good job! And, BC great point. Colon Cancer is going to be big for TLT.
Comment by Dumbledorf on Jul 03, 2023 12:44pm
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250